CO5420199A1 - Vector adenoviral recombinante para el tratamiento de cirrosis hepatica - Google Patents

Vector adenoviral recombinante para el tratamiento de cirrosis hepatica

Info

Publication number
CO5420199A1
CO5420199A1 CO00069981A CO00069981A CO5420199A1 CO 5420199 A1 CO5420199 A1 CO 5420199A1 CO 00069981 A CO00069981 A CO 00069981A CO 00069981 A CO00069981 A CO 00069981A CO 5420199 A1 CO5420199 A1 CO 5420199A1
Authority
CO
Colombia
Prior art keywords
mmp
adenoviral vector
gene
therapeutic
recombinant adenoviral
Prior art date
Application number
CO00069981A
Other languages
English (en)
Inventor
Juan Armendariz Borunda
Cordova Estuardo Aguilar
Original Assignee
Tgt Lab S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from MXPA/A/1999/008515A external-priority patent/MXPA99008515A/es
Application filed by Tgt Lab S A De C V filed Critical Tgt Lab S A De C V
Publication of CO5420199A1 publication Critical patent/CO5420199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un vector adenoviral recombinante que comprende un genoma adenoviral del cual se han deletado los marcos de lectura abiertos El y/o E3, pero que retiene la secuencia suficiente para que dicho vector adenoviral sea capaz de replicarse in vitro. Adicionalmente dicho vector contiene un gen terapéutico o una secuencia de ADN de interés regulada por promotores ubicuotos y/o promotores específicos de tejido, que codifica para proteínas terapéuticas útiles en el tratamiento de la fibrosis.El vector adenoviral recombinante de conformidad con la reivindicación 1, en donde el gen terapéutico o la secuencia de ADN clonada en dicho vector adenoviral se selecciona del gen de la metaloproteasa MMP-8 latente y activa, MMP-1, MMP-2, MMP-9 y MMP-13; gen del activador de plasminógeno derivado de uroquinasa uPA silvestre y modificado; gen del receptor truncado tipo II de TGF-ß Y Smad7 que codifican para proteínas terapéuticas que degradan el exceso de proteínas colagénicas depositadas en los órganos cirróticos. El vector adenoviral recombinante de conformidad con la reivindicación 3, en donde el gen terapéutico es una secuencia de ADN que se selecciona del gen del factor de crecimiento para hepatocitos HGF, que codifica para proteínas estimuladoras de regeneración hepática con la finalidad de restablecer las funciones normales del hígado.El vector adenoviral recombinante de conformidad con la reivindicación 1, en donde las proteínas terapéuticas para el tratamiento de la fibrosis son la proteína MMP-8 latente y activa, MMP-1, MMP-2, MMP-9 y MMP-13; uPA silvestre y/o modificado; receptor truncado tipo II de TGF-ß; betaglycano; HGF y Smad7. El vector adenoviral recombinante de conformidad con la reivindicación 1, que comprende además el envío de los genes terapéuticos o secuencias de ADN que codifican para proteínas terapéuticas para el tratamiento de fibrosis en los hígados con cirrosis. <EMI FILE="00069981_1" ID="1" IMF=JPEG >
CO00069981A 1999-09-17 2000-09-15 Vector adenoviral recombinante para el tratamiento de cirrosis hepatica CO5420199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA/A/1999/008515A MXPA99008515A (es) 1999-09-17 Vectores adenovirales recombinantes y su utilidad en el tratamiento de diversos tipos de fibrosis hepática, renal, pulmonar y cicatrices hipertróficas

Publications (1)

Publication Number Publication Date
CO5420199A1 true CO5420199A1 (es) 2004-07-30

Family

ID=19745116

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00069981A CO5420199A1 (es) 1999-09-17 2000-09-15 Vector adenoviral recombinante para el tratamiento de cirrosis hepatica

Country Status (12)

Country Link
US (3) US20030003077A1 (es)
EP (1) EP1221490B1 (es)
JP (1) JP4173663B2 (es)
AR (1) AR025692A1 (es)
AU (1) AU7322600A (es)
CA (1) CA2385538C (es)
CO (1) CO5420199A1 (es)
DE (2) DE1221490T1 (es)
ES (1) ES2183752T3 (es)
HK (1) HK1049860B (es)
PE (1) PE20010610A1 (es)
WO (1) WO2001021761A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247620B2 (en) 2001-05-09 2007-07-24 Anges Mg, Inc. Method of treating skin wounds with vectors encoding hepatocyte growth factor
WO2003086278A2 (en) 2002-04-05 2003-10-23 Board Of Regents, The University Of Texas System Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US20050036988A1 (en) * 2003-05-28 2005-02-17 Ruian Xu Compositions and methods for preventing and treating liver cirrhosis
MXPA06007207A (es) * 2003-12-23 2006-08-18 Schering Corp Metodos para la produccion de lineas de celulas a549 estables en cultivo en suspension de medio libre de suero.
JP4764872B2 (ja) * 2004-03-30 2011-09-07 インダストリー−アカデミック コオペレイション ファウンデーション，ヨンセイ ユニバーシティ リラクシン遺伝子を含む遺伝子伝達システム及びリラクシンを用いた薬剤学的組成物
US20080107630A1 (en) * 2006-04-10 2008-05-08 New York University Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus
KR102272213B1 (ko) 2014-07-08 2021-07-01 삼성전자주식회사 표적화 부위, 절단 부위, 및 세포막 투과 부위를 포함하는 융합 단백질 및 그의 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5614395A (en) * 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
IL105914A0 (en) * 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
DE4339922C1 (de) * 1993-09-03 1994-10-06 Max Planck Gesellschaft Vektor für Leber-Gentherapie
US6686198B1 (en) * 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5910487A (en) * 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US6107027A (en) 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US5980886A (en) * 1994-12-14 1999-11-09 University Of Washington Recombinant vectors for reconstitution of liver
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5883241A (en) * 1995-09-05 1999-03-16 Celltech Therapeutics Limited DNA sequences coding for a human metalloproteinase and variants thereof
AU7719596A (en) 1995-11-07 1997-05-29 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
JPH1080283A (ja) * 1996-04-25 1998-03-31 Takeda Chem Ind Ltd 新規タンパク質およびそのｄｎａ
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
DE69838061T2 (de) 1997-04-18 2008-03-13 Biogen Idec Ma Inc., Cambridge Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6436393B1 (en) * 1998-04-29 2002-08-20 Guadalupe Bilbao Adenoviral vector encoding anti-apoptotic Bcl-2 gene and uses thereof

Also Published As

Publication number Publication date
US7858368B2 (en) 2010-12-28
US20030003077A1 (en) 2003-01-02
AR025692A1 (es) 2002-12-11
US20050201984A1 (en) 2005-09-15
ES2183752T1 (es) 2003-04-01
ES2183752T3 (es) 2005-07-16
DE60017924T2 (de) 2006-03-30
EP1221490B1 (en) 2005-02-02
HK1049860B (zh) 2006-02-24
HK1049860A1 (en) 2003-05-30
PE20010610A1 (es) 2001-05-25
US8043855B2 (en) 2011-10-25
CA2385538C (en) 2007-11-06
WO2001021761A2 (es) 2001-03-29
US20040156827A1 (en) 2004-08-12
WO2001021761A3 (es) 2001-09-07
DE60017924D1 (de) 2005-03-10
JP4173663B2 (ja) 2008-10-29
CA2385538A1 (en) 2001-03-29
DE1221490T1 (de) 2003-05-28
JP2004500040A (ja) 2004-01-08
EP1221490A2 (en) 2002-07-10
AU7322600A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
Yao et al. Expression of human factor IX in mice after injection of genetically modified myoblasts.
Conrad et al. Linking transgene expression of engineered mesenchymal stem cells and angiopoietin-1–induced differentiation to target cancer angiogenesis
FR15C0003I2 (fr) Production de muteines recombinantes du facteur de coagulation sanguine viii dans des lignees de cellules humaines
ES2634500T3 (es) Terapia genética celular mixta
CY1115582T1 (el) Νεα πρωτεϊνη υποδοχεα αιμοποιητινης, nr10
DE69332538T2 (de) Cis elemente des ölkörperproteins als regulationische signale
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
RU2002124123A (ru) Модифицированный фактор viii
ES2308790T3 (es) Celulas sensibles al tgf-beta 1 derivadas de medula osea.
CO5420199A1 (es) Vector adenoviral recombinante para el tratamiento de cirrosis hepatica
ATE352561T1 (de) Pgc-1, ein neuartiger ppar-gamma-koaktivator aus braunem fettgewebe
DE69834565D1 (de) Schnell erzeugung von stabilen säugertier-zellinien mit gewinnung eines hohen gehalts von recombinanten proteine
JPWO2020081568A5 (es)
PT1007559E (pt) Celulas geneticamente modificadas que expressam as proteinas morfogeneticas do osso
ES2168459T3 (es) Secuencias amplificadoras derivadas del gen de la desmina, vectores que llevan estas secuencias y sus utilizaciones para la produccion de proteinas.
ES2226597T1 (es) Vectores recombinantes virales y no virales que contienen el gen humano de urokinasa del activador del plasminogeno y su utilizacion en el tratamiento de varios tipos de fibrosis hepatica, renal, pulmonar, pancreatica y cardiaca y cicatrices hipertroficas.
WO2002050111A3 (en) Isolated laminin 10
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
ATE517999T1 (de) Adenovirale vektoren zur behandlung der erkrankungen
CA2447300A1 (en) Cell-specific replication-competent vector
FI120501B (fi) p53-proteiinin pitoisuuksia säätelevien kalpaiinin aktiivisuuden inhibiittorien käyttö syöpälääkkeiden valmistuksessa
DE69332373T2 (de) Menschlicher epidermaler Gen-Promotor
Dichek Gene transfer in the treatment of thrombosis
Chen et al. Retroviral endostatin gene transfer inhibits human colon cancer cell growth in vivo
ATE355385T1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken

Legal Events

Date Code Title Description
FD Application lapsed